TNF and COVID-19: The decreased incidence of COVID-19 in patients treated with anti-TNFα and anti-proinflammatory ILs compounds underline the potential interest of these medications for further studies to open novel possible therapeutic strategies to avoid serious COVID-19 manifestations.